Background/Objective: Gastrointestinal tract cancers may have been severely affected by the COVID-19 pandemic. The limitations of digestive endoscopy, the fear effect, and restrictions on hospital admissions during the pandemic may have delayed the presentation of patients to hospitals and surgical procedures and may have impacted overall survival. Methods: We conducted an observational, cross-sectional study of esophageal, gastric, small bowel, and colorectal cancer patients admitted to our hospital between 1 January 2018 and 31 December 2021. We analyzed the hospitalization rates, pathological type, the onset by complications, staging, and surgery during the pandemic compared to a pre-pandemic period (January 2018–December 2019). Results: During 2018–2021, 1613 patients with malignant gut tumors were admitted to our hospital (112 esophageal and eso-cardial tumors, 419 gastric tumors, 34 small bowel tumors, and 1058 colorectal tumors). Admission was reduced by 30.3% for esophageal and eso-cardial malignant tumors, 27.6% for gastric tumors, and 17.3% for malignant colorectal tumors. For esophageal and eso-cardial tumors, a higher frequency of stenosing tumors and palliative gastrostomies was noted. More stage III gastric cancers and a lower rate of vascular invasion were recorded during the pandemic. No differences regarding small bowel tumors were noted. In colorectal tumors, slightly more stage II cancers and more stenosing tumors were recorded, but occlusive, bleeding, and perforated tumors were similar; also, surgical rates were similar, with a two-fold higher perioperative mortality. The overall survival of gastric and colorectal carcinoma was higher during the pandemic (but with no statistical significance), although a clear explanation has not emerged. Conclusions: The impact of the COVID-19 pandemic on gut cancer included a significantly lower rate of newly diagnosed admissions, more stage II colorectal and stage III gastric carcinomas, a two-fold higher perioperative mortality for colorectal carcinoma, and a trend for a surprisingly higher overall survival for gastric and colorectal tumors (but without statistical significance). Future research is necessary for assessing long-term impact.

(1) Background: Bacterial infections are frequently encountered in liver cirrhosis and may be associated with a dismal prognosis. Over recent decades, antibiotic resistance has increased, which may be linked to higher mortality. (2) Methods: We conducted a retrospective study between 2018 and 2024, evaluating all patients with cirrhosis and ascites admitted to our hospital. Antimicrobial susceptibility testing was performed on all bacterial isolates. Multivariate analysis was used to identify predictive risk factors for in-hospital death. (3) Results: In total, 806 patients were identified during the study period; 78 had spontaneous bacterial peritonitis (SBP), 6 had bacterascites, 74 had Clostridioides difficile infection (CDI), 27 had culture-positive pneumonia, 24 had urinary tract infection, and 20 had bloodstream infection (BSI). Antibiotic resistance rates were high, with multidrug-resistant (MDR) strains detected in 70.3% of cases. The isolated pathogens included MRSA (65.9%), ESBL-producing Gram-negative bacilli (18.5%), and carbapenem-resistant Gram-negative strains (31.1%); only one case of vancomycin-resistant Enterococcus (VRE) was recorded. In multivariate analysis, liver disease severity; AKI and ACLF presence; multiple infection sites; and culture-positive pneumonia, BSI, and SBP were associated with higher mortality. Gram-negative infections were also associated with higher mortality rates. (4) Conclusions: In total, 22.1% of patients hospitalised with cirrhosis and ascites had at least one confirmed bacterial infection. Increased antibiotic resistance and a high proportion of MDR were recorded. The severity of liver disease, AKI and ACLF presence, the presence of pneumonia, BSI, and SBP, Gram-negative and multiple infection sites were associated with higher mortality.